In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Theriva Biologics (TOVX – Research Report), with a price target of $4.00. The company’s shares opened today at $0.75.
McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Therap, SELLAS Life Sciences Group, and Oncolytics Biotech. According to TipRanks, McCarthy has an average return of -34.2% and a 17.79% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theriva Biologics with a $4.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.39 and a one-year low of $0.39. Currently, Theriva Biologics has an average volume of 77.99K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Read More on TOVX:
- Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference
- Theriva Biologics announces 1st patient dosed in VIRAGE Phase 2b trial
- Theriva Biologics announces dosing of first patient in Phase 1 trial of VCN-01
- Theriva Biologics to Participate in Upcoming Investor Conferences
